

Being involved in evaluation of medicines: the case of Scientific Advisory Group meetings

Breda Flood

EFA President

breda.flood@efanet.org

www.efanet.org



Twofold involvement

Patients are consulted in:

- **Scientific Advice Working Party (SAWP)**
- **Scientific Advisory Group (SAG)**

Ad-hoc disease specific advisory groups providing independent recommendations on scientific or technical matters relating to the evaluation of medicines; **patient perspective helps to provide valuable insights, such as acceptable levels of associated risks**

Standing working party providing scientific advice and protocol assistance to the applicants for a market authorisation at any stage and on any area of drug development (quality, non-clinical or clinical); **patients are asked to give their personal experience on the issues being discussed**

Patients' views matters

Feasibility of the study proposed

Relevant patient population

Relevant patient outcomes

Comparator or not

Duration of study

Safety concerns

Benefit-risk balance

Guidelines

Clinical impact of risks

Clinical meaningfulness of benefits

Myths and truths

- Real life examples provided
- Bringing patients' preferences into the system
- Actual impact on the outcomes

Pros



- Too technical?
- Little impact?
- Documents overload
- Strict deadlines

Cons



To know more: <http://www.youtube.com/watch?v=Qt8lXQ5c358>

Thank you for your attention!

European Federation of Allergy and Airways Diseases
Patients' Associations (EFA)

EFA 35 Rue du Congrès
1000 Brussels, Belgium
www.efanet.org



Co-funded by
the Health Programme
of the European Union

